Objective: We evaluated the clinicopathologic factors associated with gastric neuroendocrine carcinoma (NEC) in patients who underwent surgical resection. Gastric NEC is rare, accounting for only about 0.6% of all malignant gastric tumors. Neither its pathogenesis nor its treatment has been fully established. Methods: We assessed 10 patients with gastric NEC who underwent surgical resection in our hospital between September 2007 and June 2019. Results: The patients consisted of 9 men and 1 woman, aged 63 to 78 years. The tumors were localized in the upper region (n = 5), middle region (n = 3), and lower region (n = 2). The macroscopic types were evaluated as 0-IIc (n = 3), 1 (n = 3), 2 (n = 1), 3 (n = 2), and 4 (n = 1). The stages were ascertained as IA (n = 3), IIB (n = 3), IIIA (n = 2), IIIB (n = 1), and IIIC (n = 1). Radical resection was performed in all the patients. After surgery, relapse-free survival was achieved in 6 patients. The mean postoperative survival time was 63.5 months. On immunostaining, 6 patients were positive for CD56, and all were positive synaptophysin and chromogranin A. Of the 10 patients, standard-type adenocarcinoma was concomitantly present in 6. Conclusions: Some patients with surgically resected gastric NEC survived over a long period, suggesting the usefulness of radical resection. In future studies, the pathogenesis of gastric NEC should be fully clarified, and therapeutic strategies must be further developed.